Equitable distribution was our North Star from day one. In order to ensure that every country that chooses the Pfizer-BioNTech COVID-19 vaccine can have access to it, two conditions had to be met: a price that all countries can afford and reliable manufacturing to enable broad global distribution.

To date (5 December 2021), Pfizer and BioNTech have shipped 2.25 billion vaccines to 163 countries and territories in every region of the world, including:

- 55 countries / territories in Europe
- 37 countries in Africa
- 24 countries in Asia/Pacific
- 15 countries / territories in Middle East
- 32 countries in the Americas
- 37 countries in Africa

At the Global Health Summit in Rome in May 2021, we pledged to provide 2 billion vaccine doses to low and middle-income countries in 2021 and 2022 - at least 1 billion doses each year. To date, we are on track to meet this commitment for 2021 and have delivered more than 808 million doses to 95 of these countries.

Supply Pathways:

- Direct supply agreements to governments of countries around the world.
- A direct supply agreement with COVAX for up to 40 million doses in 2021.
- Agreement to provide 1 billion doses to the United States at a not-for-profit price to go to low and lower-middle income countries and the African Union.
- Targeted humanitarian donation programs where needed for vulnerable populations.

Tiered Pricing Policy:

Starting in 2020, we offered our vaccine through tiered pricing:

- The price for wealthier nations would be about the cost of a takeaway meal, and would be offered at a price that enables governments to provide it to their populations for free.
- Middle-income countries were offered doses at roughly half that price.
- Low-income countries were offered doses at a not for profit price.

With our industry partners, we also share the five commitments¹ to urgently advance vaccine equity:

- Step up dose sharing
- Continue to optimize production
- Call out trade barriers to be eliminated
- Support country readiness
- Drive innovation
Fundamental to our access strategy is work to globally scale up manufacturing. From the outset, we have taken a relentless focus on efficiency to enable us to quickly scale up manufacturing. Reducing production timelines has been achieved by:

- Doubling our batch sizes to minimize time between batches and increasing the yield per batch
- Expanding the supply of raw material from existing suppliers
- Adding additional formulation rooms to increase formulation capacity by over 3x
- Adding high-speed packing lines to increase the daily ship rate
- Bringing on new suppliers

Almost 50% reduction from start to vial-ready production

We are also partnering to build up scale. As of 23 November 2021, the Pfizer-BioNTech global COVID-19 vaccine supply chain and manufacturing network now spans four continents and includes more than 20 facilities.

Recommendations for policymakers:

Support open trade. The vaccine manufacturing process depends on a complex global network of suppliers of raw materials and equipment, competing for materials between pharmaceutical manufacturers, and other industries. Trade bottlenecks – including export restrictions, tariffs, and customs red tape – add cost and delay vaccine manufacturing and scale up.

Invest in resilient health systems. Beyond manufacturing, vaccine deployment requires scale up of ultra-cold chain capacity, trained health care personnel, and more resilient health system infrastructure to broadly support delivery, particularly in low and lower-middle income countries.

Enable innovation. Manufacturers are engaged in unprecedented collaboration to support vaccine development and manufacturing, thanks in part to intellectual property (IP) protections and other pro-innovation policies. Additional research and collaboration continue to be needed to find solutions for special populations (e.g. children) and overcome new variants of the virus.